Literature DB >> 27582427

Clonal cooperativity in heterogenous cancers.

Hengbo Zhou1, Deepika Neelakantan2, Heide L Ford3.   

Abstract

Tumor heterogeneity is a major obstacle to the development of effective therapies and is thus an important focus of cancer research. Genetic and epigenetic alterations, as well as altered tumor microenvironments, result in tumors made up of diverse subclones with different genetic and phenotypic characteristics. Intratumor heterogeneity enables competition, but also supports clonal cooperation via cell-cell contact or secretion of factors, resulting in enhanced tumor progression. Here, we summarize recent findings related to interclonal interactions within a tumor and the therapeutic implications of such interactions, with an emphasis on how different subclones collaborate with each other to promote proliferation, metastasis and therapy-resistance. Furthermore, we propose that disruption of clonal cooperation by targeting key factors (such as Wnt and Hedgehog, amongst others) can be an alternative approach to improving clinical outcomes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clonal cooperativity; Epithelial to mesenchymal transition; Metastasis; Tumor heterogeneity

Mesh:

Year:  2016        PMID: 27582427      PMCID: PMC5330947          DOI: 10.1016/j.semcdb.2016.08.028

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  181 in total

Review 1.  Matrix metalloproteinases in tumor invasion and metastasis.

Authors:  I Stamenkovic
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

2.  IkappaBalpha and IkappaBalpha /NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2.

Authors:  M Prigent; I Barlat; H Langen; C Dargemont
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

Review 3.  Molecular regulation of vessel maturation.

Authors:  Rakesh K Jain
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 4.  Rethinking clinical trials for cytostatic drugs.

Authors:  Andrew W Millar; Kevin P Lynch
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

Review 5.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks.

Authors:  Yves Pommier; Olivier Sordet; Smitha Antony; Richard L Hayward; Kurt W Kohn
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

6.  Mechanisms of cell death associated with death-inducing factors from genomically unstable cell lines.

Authors:  Shruti Nagar; Leslie E Smith; William F Morgan
Journal:  Mutagenesis       Date:  2003-11       Impact factor: 3.000

Review 7.  Mechanisms of cancer drug resistance.

Authors:  Michael M Gottesman
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 8.  Cancer genes and the pathways they control.

Authors:  Bert Vogelstein; Kenneth W Kinzler
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

9.  Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations.

Authors:  Masayuki Sanada; Yasumitsu Takagi; Riyoko Ito; Mutsuo Sekiguchi
Journal:  DNA Repair (Amst)       Date:  2004-04-01

10.  Competition and natural selection in a mathematical model of cancer.

Authors:  John D Nagy
Journal:  Bull Math Biol       Date:  2004-07       Impact factor: 1.758

View more
  18 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 2.  Evolutionary scalpels for dissecting tumor ecosystems.

Authors:  Daniel I S Rosenbloom; Pablo G Camara; Tim Chu; Raul Rabadan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-05       Impact factor: 10.680

3.  Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Aishwarya Iyer; Dylan Hennessey; Sandra O'Keefe; Jordan Patterson; Weiwei Wang; Gane Ka-Shu Wong; Robert Gniadecki
Journal:  Blood Adv       Date:  2020-06-09

Review 4.  Limiting tumor seeding as a therapeutic approach for metastatic disease.

Authors:  Asurayya Worrede; Olimpia Meucci; Alessandro Fatatis
Journal:  Pharmacol Ther       Date:  2019-03-12       Impact factor: 12.310

5.  Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment.

Authors:  Vu T A Vo; Sohyun Kim; Tuyen N M Hua; Jiwoong Oh; Yangsik Jeong
Journal:  Commun Biol       Date:  2022-06-16

6.  Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy.

Authors:  Ramanpreet Kaur; Chen Qian; Anthony DiNatale; Jieyi Zhang; Michael Marchioli; Darin Ipe; Maria Castelli; Chris M McNair; Gaurav Kumar; Olimpia Meucci; Alessandro Fatatis
Journal:  Oncogene       Date:  2022-01-08       Impact factor: 8.756

Review 7.  A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Authors:  Christian M Schürch; Leo Rasche; Leonie Frauenfeld; Niels Weinhold; Falko Fend
Journal:  Virchows Arch       Date:  2019-12-17       Impact factor: 4.064

8.  Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity.

Authors:  Odessa Schillaci; Simona Fontana; Francesca Monteleone; Simona Taverna; Maria Antonietta Di Bella; Dolores Di Vizio; Riccardo Alessandro
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

Review 9.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

10.  Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.

Authors:  Seung Woo Lee; Taekyu Lee; Hae Jung Sul; Ki Cheol Park; Joonhong Park
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.